Zealand Pharma to participate in the Jefferies London Healthcare Conference
Press Release – No. 11 / 2024
Zealand Pharma to participate in the Jefferies London Healthcare Conference
Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies London Healthcare Conference at 9:30 a.m. GMT (10:30 a.m. CET) on Thursday, November 21, 2024.
A live audio webcast of the fireside chat will be available at https://wsw.com/webcast/jeff315/zeal/1844976 and accessible through the company’s website at https://www.zealandpharma.com/investors/events-presentations/ where a recording of the webcast will also be archived after the event.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Contacts:
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: AKrassowska@zealandpharma.com
Adam Lange
Investor Relations Officer
Zealand Pharma
Email: ALange@zealandpharma.com
Neshat Ahmadi
Investor Relations Manager
Zealand Pharma
Email: NeAhmadi@zealandpharma.com
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.
